Literature DB >> 23321502

Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.

Guillermo José Ruiz-Arguelles1, Guillermo José Ruiz-Delgado, Sara Velázquez-Sánchez-de-Cima, Gabriela Zamora-Ortiz.   

Abstract

A 58-year-old woman presented with rheumatoid arthritis-associated Evans syndrome (simultaneous autoimmune hemolytic anemia and autoimmune thrombocytopenic purpura); she was treated unsuccessfully with steroids, romiplostin, rituximab, immunoglobulin G, and splenectomy. The platelet count responded to the combined use of prednisone, eltrombopag, and romiplostin. It may be more reasonable to use combined treatments than sequential monotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321502     DOI: 10.1179/1607845412Y.0000000060

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  3 in total

1.  Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.

Authors:  Christian A Di Buduo; Manuela Currao; Alessandro Pecci; David L Kaplan; Carlo L Balduini; Alessandra Balduini
Journal:  Haematologica       Date:  2016-08-11       Impact factor: 9.941

2.  Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.

Authors:  Naidan Zhang; Chaixia Ji; Xiao Bao; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

Review 3.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.